ARA-290 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
Synergizes with BPC-157 for comprehensive tissue repair — ARA-290 handles neuropathic and inflammatory pathways while BPC-157 targets connective tissue and gut healing. Proper stacking requires understanding each compound's mechanism and timing.
What Is ARA-290 Stacking?
Stacking means combining ARA-290 with one or more complementary peptides to potentially achieve synergistic effects. Because different peptides work through different mechanisms, strategic combinations can target multiple pathways simultaneously.
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What Is the Best ARA-290 Stack?
Synergizes with BPC-157 for comprehensive tissue repair — ARA-290 handles neuropathic and inflammatory pathways while BPC-157 targets connective tissue and gut healing.
This combination is popular because it targets multiple mechanisms without significant overlap in side-effect profiles.
How Does ARA-290 Stack With BPC-157?
BPC-157 (Body Protection Compound-157) is a Pentadecapeptide (15 amino acids) that works through BPC-157 upregulates growth hormone receptors and promotes angiogenesis (new blood vessel formation) through the FAK-paxillin pathway, which is critica.
Combined with ARA-290's effects on neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes, this stack covers tissue repair, gut healing, tendon and ligament recovery, wound healing, neuroprotection as well.
Typical stacking protocol: ARA-290 at 2-4 mg daily once daily alongside BPC-157 at 200-500 mcg once or twice daily. See our BPC-157 guide for details.
How Do You Time a ARA-290 Stack?
When stacking, timing each injection based on half-life is important. ARA-290 has a half-life of approximately 24 hours, which influences when to administer relative to other compounds.
Some researchers inject all peptides at the same time; others stagger by 15-30 minutes. There's limited data on whether timing within the same session matters significantly.
What Should You NOT Stack With ARA-290?
Avoid stacking peptides with similar mechanisms of action at full doses — this can lead to receptor desensitization without proportional benefit. Also avoid combining compounds where side-effect profiles overlap significantly.
When in doubt, introduce one new compound at a time to isolate its effects before building a full stack.
Calculate Your ARA-290 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for ARA-290.
Open Calculator →Bottom Line on ARA-290 Stacking
Synergizes with BPC-157 for comprehensive tissue repair — ARA-290 handles neuropathic and inflammatory pathways while BPC-157 targets connective tissue and gut healing. Start with a single compound, assess response, then add complements.
See our stacking and cycling guide for general principles.
Complete Guide
ARA-290 : Benefits, Dosage, Side Effects & Research
Related Reading
- ARA-290 Dosage Guide
- ARA-290 Benefits
- ARA-290 Side Effects
- ARA-290 Cycle Guide
- ARA-290 Research
- BPC-157 Complete Guide
Research-Grade Sourcing
If you're going to research ARA-290, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is ARA-290?
ARA-290 (Erythropoietin-derived tissue-protective peptide) is a Innate repair receptor agonist, anti-inflammatory peptide. Synthetic 11-amino acid peptide engineered from the tissue-protective domain of erythropoietin (EPO). It is researched for neuropathic pain relief, inflammation reduction, nerve fiber regeneration, improved autonomic function, metabolic control in diabetes.
What is the recommended ARA-290 dosage?
Common dosages: 2-4 mg daily administered once daily via subcutaneous injection. Cycle length: 28 days typical; 8-16 weeks for extended response. Half-life: approximately 24 hours. Use our peptide calculator for exact reconstitution math.
What are the side effects of ARA-290?
Safe profile in multiple clinical trials. Minimal reported adverse events. Occasional mild injection site reactions. No serious safety concerns identified across diabetes, sarcoidosis, and neuropathy patient populations.
Is ARA-290 safe?
ARA-290 has shown a preliminary safety profile in research. Investigational. Underwent Phase II clinical trials. Not FDA-approved. All research should follow appropriate safety protocols.